Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Artemis II updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth - 2Top 10 Smash hit Computer games of the Year
- 3'Stranger Things' star debunks claims of 'unseen footage' from Season 5, Volume 2 as backlash intensifies ahead of the series finale
- 4Activists: Venezuela released just nine prisoners despite promise
- 5How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- The 10 Most Famous Style Minutes on Honorary pathway
- Scientists are getting our robotic explorers ready to help send humans to Mars
- Passover under fire: Israelis balance fatigue with cautious hope after month of war
- Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- Nature: 10 High priority Setting up camp Spots In Europe
- Investigating Inside Plan and Home Style: Change Your Residing Space
- Mississippi Insight for Jan. 11, 2026
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Israeli president concerned over proposed renaming of park
